Gyre Therapeutics
GYRE
16 hedge funds and large institutions have $15.6M invested in Gyre Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 18 closing their positions.
1,405% more capital invested
Capital invested by funds: $1.04M → $15.6M (+$14.6M)
335% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $514K
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0.41% more ownership
Funds ownership: 0.38% → 0.79% (+0.41%)
48% less funds holding
Funds holding: 31 → 16 (-15)
83% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.61M |
| 2 |
BlackRock
New York
|
+$2.44M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.66M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$267K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$316K |
| 2 |
Morgan Stanley
New York
|
-$47.1K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$44.2K |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$43.4K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$32.7K |
GYRE Hedge Fund Activity: Q4 2023 in Review
16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2023, worth a combined $15.6M — up 1,405% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of GYRE and 3 opened new positions — a net loss of 15 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $2.61M. The largest seller was Renaissance Technologies, cutting an estimated $316K.
- 16 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2023, down from 31 in Q3 2023.
- Funds reported $15.6M of Gyre Therapeutics stock for Q4 2023, up 1,405% quarter-over-quarter.
- 3 funds opened new Gyre Therapeutics positions in Q4 2023 and 18 closed out, a net change of -15 holders.
- The largest Gyre Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $2.61M added.
- The largest Gyre Therapeutics seller in Q4 2023 was Renaissance Technologies, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2023.